<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248975</url>
  </required_header>
  <id_info>
    <org_study_id>114387</org_study_id>
    <nct_id>NCT01248975</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma</brief_title>
  <official_title>A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 300mg as Compared to Adding Montelukast 10mg or Placebo Tablets QD to Fluticasone Propionate/Salmeterol 250/50mcg Diskus BID</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy and safety of adding
      GSK2190915 300mg or placebo tablets administered once daily to fluticasone
      propionate/salmeterol 250/50mcg inhalation powder administered twice daily in uncontrolled
      asthmatic subjects &gt; or = 18 years of age over the course of 6 weeks treatment.

      The secondary objectives are to undertake an exploratory analysis of the efficacy and safety
      of adding montelukast 10mg administered once daily to fluticasone propionate/salmeterol
      250/50mcg inhalation powder administered twice daily and to investigate the pharmacokinetics
      and pharmacodynamics of GSK2190915 in uncontrolled asthmatic subjects &gt; or = 18 years of age
      over the course of 6 weeks treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough (AM pre-dose and pre-rescue bronchodilator) FEV1</measure>
    <time_frame>at the end of the 6 week treatment period.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Daily trough (AM pre-dose and pre-rescue bronchodilator) AM PEF</measure>
    <time_frame>averaged over the last 3 weeks of the 6 week treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Daily PM PEF</measure>
    <time_frame>averaged over the last 3 weeks of the 6 week treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Daily (average of AM and PM)</measure>
    <time_frame>averaged over the last 3 weeks of the 6 week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Daily asthma symptom score</measure>
    <time_frame>averaged over the last 3 weeks of the 6 week treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Daily rescue salbutamol use</measure>
    <time_frame>averaged over the last 3 weeks of the 6 week treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Percentage of symptom-free days</measure>
    <time_frame>during the last 3 weeks of the 6 week treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Percentage of symptom-free nights</measure>
    <time_frame>during the last 3 weeks of the 6 week treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Percentage of rescue-free days</measure>
    <time_frame>during the last 3 weeks of the 6 week treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Percentage of rescue-free nights</measure>
    <time_frame>during the last 3 weeks of the 6 week treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Percentage of nights without awakenings due to asthma</measure>
    <time_frame>during the last 3 weeks of the 6 week treatment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Proportion of subjects withdrawn due to lack of efficacy</measure>
    <time_frame>during the last 3 weeks of the 6 week treatment period.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FP/SAL 250/50mcg BID plus placebo BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>P/SAL 250/50mcg BID plus placebo BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FP/SAL 250/50mcg BID</intervention_name>
    <description>FP/SAL 250/50mcg BID</description>
    <arm_group_label>FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)</arm_group_label>
    <arm_group_label>FP/SAL 250/50mcg BID plus placebo BID</arm_group_label>
    <arm_group_label>FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2190915 200mg QD (AM)</intervention_name>
    <description>GSK2190915 200mg QD (AM)</description>
    <arm_group_label>FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2190915 100mg QD (AM)</intervention_name>
    <description>GSK2190915 100mg QD (AM)</description>
    <arm_group_label>FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast 10mg QD (PM)</intervention_name>
    <description>Montelukast 10mg QD (PM)</description>
    <arm_group_label>FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablets (2) (AM)</intervention_name>
    <description>Placebo tablets (2) (AM)</description>
    <arm_group_label>FP/SAL 250/50mcg BID plus placebo BID</arm_group_label>
    <arm_group_label>FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule (PM)</intervention_name>
    <description>Placebo capsule (PM)</description>
    <arm_group_label>FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)</arm_group_label>
    <arm_group_label>FP/SAL 250/50mcg BID plus placebo BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 years of age or older

          -  Non-, former or current smokers with a documented smoking history of ≤ 10 pack years

          -  Asthma diagnosis as defined by the National Institutes of Health

          -  Best FEV1 of 50% to &lt;80% of the predicted normal value

          -  For current and former smokers, a post-albuterol FEV1/FVC ratio of &gt;0.70 at Visit 1/1a
             (between 5:00AM and 12:00 noon)

          -  ≥ 12% and ≥200mL reversibility of FEV1

          -  Must have been using FP/SAL 250/50mcg inhalation powder BID for at least 2 weeks just
             prior to Visit 1.

          -  Must be able to replace their current short-acting beta2-agonists with albuterol
             inhalation aerosol

          -  Must be able and willing to give written informed consent to take part in the study.

          -  Must be able and willing to comply with all aspects of the study including completion
             of daily e-Diary.

        Exclusion criteria:

          -  History of life-threatening asthma

          -  Recent asthma exacerbation

          -  Concurrent respiratory disease

          -  Recent respiratory infection

          -  Liver disease

          -  Other concurrent diseases/abnormalities

          -  Oral candidiasis

          -  Drug allergy

          -  Milk protein allergy

          -  Immunosuppressive Medications

          -  Administration of systemic, oral or depot corticosteroids within 12 weeks of Visit 1

          -  OATP1B1 substrates within 4 weeks of Visit 1

          -  Cytochrome P450 3A4 (CYP 3A4) Inhibitors

          -  Cytochrome P450 3A4 (CYP 3A4) Inducers

          -  Investigational Medications

          -  Compliance: any infirmity, disability, or geographical location which seems likely (in
             the opinion of the Investigator) to impair compliance with any aspect of this study
             protocol

          -  Affiliation with Investigator's Site
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ruse</city>
        <zip>7000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-084</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>93-329</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49051</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Donetsk</city>
        <zip>83099</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kiev</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kiev</city>
        <zip>3680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>02091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>02232</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zaporizhia</city>
        <zip>69035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Poland</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <disposition_first_submitted>April 12, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>April 12, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 16, 2012</disposition_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>GSK2190915</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>114387</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114387</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114387</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114387</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114387</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114387</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114387</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <pending_results>
    <submitted>August 2, 2017</submitted>
    <returned>February 5, 2018</returned>
    <submitted>February 13, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

